In contrast, other authors have found that GSTM1 null/GSTT1 null genotype exposed significantly subjects to develop CML when compared to GSTM1 present/GSTT1 present genotype (Bhat et al. 2012; Özten et al. 2012), some authors, reported that subjects with GSTM1 present/GSTT1 null genotype were 2.5 times more likely to develop CML when compared to GSTM1 null/GSTT1 present genotype (Özten et al. 2012). Here, GSTM1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.